Brussels' AI Device Cybersecurity: Pure Global's Hidden Risks

In this episode of MedTech Global Insights, we dissect the rapidly evolving regulatory landscape in the European Union. As AI and software-based medical devices become more prevalent, regulators are shifting their focus beyond clinical efficacy to a critical new area: cybersecurity. We explore the latest draft implementing acts and new harmonised standards discussed last week that are creating a complex new layer of requirements for MedTech innovators. This isn't just about IT; it's about patient safety and market access. A specific case: A US-based scaleup with a CE-marked, AI-powered diagnostic platform suddenly faces a notified body audit focused on new cybersecurity mandates. Their existing risk management file doesn't address threat modeling for state-sponsored cyber attacks, and their post-market plan lacks active vulnerability monitoring, putting their market presence in jeopardy. This Episode's Key Questions: - Is your current Quality Management System prepared for the new EU cybersecurity requirements for medical devices? - How can you prove your AI device is secure against threats that could alter its clinical performance? - What specific documentation is now required to demonstrate robust cybersecurity lifecycle management? - Why is your old approach to software validation no longer sufficient for connected devices? - What are the mandatory new elements of a post-market surveillance plan for AI device cybersecurity? - How do you handle vulnerability disclosure without causing a panic among users and regulators? - Are your third-party software components creating a regulatory risk you haven't accounted for? For more information, contact us at [email protected], visit our website at https://pureglobal.com/, or access our FREE AI tools and medical device database at https://pureglobal.ai/.